Agilent Technologies Stock News

Immuno Oncology Assays Market: An in-depth analysis of statistics on current and emerging trends provides clarity regarding Immuno Oncology Assays Market dynamics. The report includes Porter''s five forces to analyze the importance of various characteristics such as understanding of suppliers

Agilent Technologies (A) closed at $156.78 in the latest trading session, marking a +1.83% move from the prior day.

Clifford Swan Investment Counsel LLC reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 5.5% in the 3rd quarter, Holdings Channel reports. The firm owned 175,803 shares of the medical research companys stock after selling 10,240 shares during the quarter. Clifford Swan Investment Counsel LLCs holdings in Agilent Technologies were worth $27,612,000 as of its []

Clifford Swan Investment Counsel LLC lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 5.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 175,803 shares of the medical research companys stock after selling 10,240 shares during the quarter. Clifford Swan Investment Counsel LLCs holdings in Agilent Technologies were worth $27,612,000 as []

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Independent Advisor Alliance increased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 3.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 9,009 shares of the medical research companys stock after acquiring an additional 278 shares during the period. Independent Advisor Alliances holdings in Agilent Technologies were worth $1,419,000 at the end of []

The antibody is called immunoglobulin which is produced by plasma cells to certain antigens. The widespread of Covid-19 has driven the Global Research antibody Market. The detection & diagnosis of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM/IgG

Janney Montgomery Scott LLC raised its stake in Agilent Technologies, Inc. (NYSE:A) by 1.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,617 shares of the medical research companys stock after acquiring an additional 231 shares during the period. Janney Montgomery Scott LLCs []

Agilent Technologies, Inc. (NYSE:A) CEO Michael R. Mcmullen sold 123,459 shares of the firms stock in a transaction on Monday, December 20th. The shares were sold at an average price of $148.82, for a total value of $18,373,168.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be []

DUBLIN--(BUSINESS WIRE)--The "Bioinformatics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global bioinformatics market is expected to grow from $9.38 billion in 2020 to $10.57 billion in 2021 at a compound annual growth rate (CAGR) of 12.7%. The market is expected to reach $18.46 billion in 2025 at a CAGR of 15%. Major players in the bioinformatics market are Agilent Technologies, Illumina, QIAGEN, Affymetrix and

The North America Anatomic Pathology Market is expected to reach US$ 13,970.95 million by 2028 from US$ 8,870.41 million in 2021; it is estimated to grow at a CAGR of 6.7% from 2021 to 2028. The anatomic pathology is a significant

Signaturefd LLC raised its position in shares of Agilent Technologies, Inc. (NYSE:A) by 5.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,751 shares of the medical research companys stock after purchasing an additional 252 shares during the quarter. Signaturefd LLCs holdings []

The Biomarker Technologies Market research report provides broad, subjective bits of knowledge on the potential and specialty portions or regions displaying good growth. The Biomarker Technologies Market research report comprehensively investigates the current and developing business sector patterns and openings